Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1998;92:308-311
© 1998 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mittendorf, R
Right arrow Articles by Lee, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mittendorf, R
Right arrow Articles by Lee, K.

Articles

If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact?

R Mittendorf, P Pryde, B Khoshnood, and KS Lee

The Magnesium and Neurologic Endpoints Trial was a randomized controlled trial (RCT) done to learn whether or not receiving magnesium sulfate during preterm labor could prevent cerebral palsy. Unexpectedly, in the tocolytic arms of the trial, seven (including one set of twins) of 46 cases assigned to receive magnesium ended in total pediatric mortality (fetal + neonatal + postneonatal), compared to none of 47 cases assigned to other tocolytics ending in death. The difference between the two treatment arms is highly statistically significant (risk difference 15.2%; 95% confidence interval 4.8, 25.6; P = .006). If this relationship is confirmed by experimentation with animals or through the conduct of a large RCT at other institutions, it is possible that tocolytic magnesium will be found to be associated with the deaths of several thousand newborns in the United States annually. If the true excess total pediatric mortality is 10%, and if magnesium accounts for 40% of all tocolytics used, then tocolytic magnesium increases the absolute number of infant deaths by about 4800 every year.


This article has been cited by other articles:


Home page
 Obstet GynecolHome page
D. A. Grimes and K. Nanda
Magnesium sulfate tocolysis: time to quit.
Obstet. Gynecol., October 1, 2006; 108(4): 986 - 989.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
R. SCUDIERO, B. KHOSHNOOD, P. G. PRYDE, K.-S. LEE, S. WALL, and R. MITTENDORF
Perinatal Death and Tocolytic Magnesium Sulfate
Obstet. Gynecol., August 1, 2000; 96(2): 178 - 182.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. G. Pryde, R. Mittendorf, E. R. Norwitz, and J. N. Robinson
The Control of Labor
N. Engl. J. Med., December 30, 1999; 341(27): 2098 - 2099.
[Full Text]

Home page
 Obstet GynecolHome page
D. McNellis, D. Hirtz, R. Mittendorf, K.-S. Lee, B. Khoshnood, and P. Pryde
IF TOCOLYTIC MAGNESIUM SULFATE IS ASSOCIATED WITH EXCESS TOTAL PEDIATRIC MORTALITY, WHAT IS ITS IMPACT?
Obstet. Gynecol., January 1, 1999; 93(1): 159 - 160.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American College of Obstetricians and Gynecologists.